%0 Journal Article
%A Cabo, Mariona
%A Offringa, Rienk
%A Zitvogel, Laurence
%A Kroemer, Guido
%A Muntasell, Aura
%A Galluzzi, Lorenzo
%T Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
%J OncoImmunology
%V 6
%N 12
%@ 2162-4011
%C Abingdon
%I Taylor & Franics
%M DKFZ-2021-03066
%P e1371896 -
%D 2017
%Z POF Topic: 317
%X The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells - such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) - or their ligands - such as CD274 (best known as PD-L1) - have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development.
%K CD137 (Other)
%K CD40 (Other)
%K GITR (Other)
%K ICOS (Other)
%K OX40 (Other)
%K PD-1 (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29209572
%2 pmc:PMC5706611
%R 10.1080/2162402X.2017.1371896
%U https://inrepo02.dkfz.de/record/178057